Rating of Russian Pharmaceutical Distributors (Q1 – Q2 2017)
The first half of 2017 was very vigorous for Russian pharmaceutical distributors. First, the wholesalers initiated several large, if not to say core, transactions. Representatives of Marathon Pharma announced a global partnership with Nacimbio, which is interesting in the first place for the scale of the public-private partnership. This should be a logical completion of the infrastructure of the pharmaceutical assets of Rostec. However, not every company managed to get larger, in particular, once one of the largest players of the Russian pharmaceutical wholesale Rosta sold its chain Raduga to Doktor Stoletov. While the future of Doktor Stoletov is quite obvious after the end of the integration period, the future of Rosta is rather ambiguous.
Secondly, the distributors continued the development of their own retail through the purchase of existing pharmacy chains. In particular, Grand Capital bought the chain Metr (Bryansk), and Protek bought DOMfarma (Kolomna). Both Metr and DOMfarma are very strong regional chains with a long history.
Finally, in addition to the development of the core competencies of wholesale companies, the tendency of diversifying the investment portfolio of certain Russian pharmaceutical wholesalers into non-pharmaceutical areas was quite evident. In particular, Aleksei Repik (R-Pharm) announced investments in a hotel complex in Yaroslavl, and Viktor Kharitonin (Pharmstandard) bought the shopping center Gorbushkin Dvor.
Read more about rating of Russian pharmaceutical Distributors(Q1 2017 performance) here: http://rncph.com/news/31_05_2017
See the detailed rating in the newspaper Farmatsevtichesky Vestnik (No. 26, 08/29/2017).
Tab 1. Top 15 pharmaceutical distributors with the largest market share of direct shipments of drugs (including preferential shipments), in monetary terms (Q1 – Q2 2017)